免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.01.009

Abstract

Abstract: Pancreatic cancer is extremely malignant.It is usually in the advanced stage when discovered,and the median survival time is extremely short,which seriously threatens human life and health.Compared with other cancers,the treatment progress made in recent years is also very limited.Immune checkpoint inhibitors(ICIs),as emerging drugs in recent years,have achieved exciting therapeutic effects in multiple tumors,but they have encountered Waterloo in pancreatic cancer.The reasons why pancreatic cancer is not sensitive to ICIs treatment may include the following aspects:first,pancreatic cancer is weak antigenic and insufficient to activate the immune system;second,the dense connective tissue in the immune microenvironment hinders drug infiltration;third,the immunosuppressive microenvironment formed by a large number of immunosuppressive cells inhibits the activation of T lymphocytes.However,the latest research shows that ICIs-based combination therapy can increase the sensitivity of pancreatic cancer to ICIs treatment by increasing the exposure of tumor antigens,breaking the interstitial barrier,and improving the immunosuppressive microenvironment,thereby exerting a positive anti-tumor effect.This article reviews the progress made in the field of pancreatic cancer treatment based on ICIs-based combination therapy.

Key words: Pancreatic cancer, Immune checkpoint inhibitors, Combination therapy

CLC Number:

R735.9

LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer[J]. Journal of Practical Oncology, 2022, 36(1): 49-53.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/49

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Klebanoff CA,Gattinoni L,Restifo NP.CD8⁺T-cell memory in tumor immunology and immunotherapy[J].Immunol Rev,2006,211(1):214-224.
3 Aldarouish M,Wang C.Trends and advances in tumor immunology and lung cancer immunotherapy[J].J Exp Clin Cancer Res,2016,35(1):157.
4 Dany M,Nganga R,Chidiac A,et al.Advances in immunotherapy for melanoma management[J].Hum Vaccin Immunother,2016,12(10):2501-2511.
5 Luchini C,Bibeau F,Ligtenberg MJL,et al.ESMO recommendations on microsatellite instability testing for immunotherapy in cancer,and its relationship with PD-1/PD-L1 expression and tumour mutational burden:a systematic review-based approach[J].Ann Oncol,2019,30(8):1232-1243.
6 Clark CE,Hingorani SR,Mick R,et al.Dynamics of the immune reaction to pancreatic cancer from inception to invasion[J].Cancer Res,2007,67(19):9518-9527.
7 Steimle V,Siegrist CA,Mottet A,et al.Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA[J].Science,1994,265:106-109.
8 Knudsen ES,Vail P,Balaji U,et al.Stratification of pancreatic ductal adenocarcinoma:combinatorial genetic,stromal,and immunologic markers[J].Clin Cancer Res,2017,23:4429-4440.
9 Sideras K,Braat H,Kwekkeboom J,et al.Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies[J].Cancer Treat Rev,2014,40(4):513-522.
10 Reits EA,Hodge JW,Herberts CA,et al.Radiation modulates the peptide repertoire,enhances MHC class I expression,and induces successful antitumor immunotherapy[J].J Exp Med,2006,203(4):1259-1271.
11 Xie C,Duffy AG,Brar G,et al.Correction:Immune checkpoint blockade in Combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2021,27(1):358-358.
12 Aglietta M,Barone C,Sawyer MB,et al.A phase I dose escalation trial of tremelimumab(CP-675,206)in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer[J].Ann Oncol,2014,25(9):1750-1755.
13 Wainberg ZA,Hochster HS,George B,et al.Phase I study of nivolumab(nivo)+ nab-paclitaxel(nab-P)± gemcitabine(Gem)in solid tumors:Interim results from the pancreatic cancer(PC)cohorts[J].Clin Oncol,2017,35:412.
14 Weiss GJ,Blaydorn L,Beck J,et al.Phase Ib/II study of gemcitabine,nab-paclitaxel,and pembrolizumab in metastatic pancreatic adenocarcinoma[J].Invest New Drugs,2018,36:96-102.
15 Soares KC,Rucki AA,Wu AA,et al.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J].J Immunother,2015,38(1):1-11.
16 Le DT,Lutz E,Uram JN,et al.Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer[J].J Immunother,2013,36(7):382-389.
17 Ady JW,Heffner J,Klein E,et al.Oncolytic viral therapy for pancreatic cancer:current research and future directions[J].Oncolytic Virother,2014,3:35-46.
18 Noonan AM,Farren MR,Geyer SM,et al.Randomized phase 2 trial of the oncolytic virus Pelareorep(Reolysin)in upfront treatment of metastatic pancreatic adenocarcinoma[J].Mol Ther,2016,24:1150-1158.
19 Kazerounian S,Lawler J.Integration of pro-and anti-angiogenic signals by endothelial cells[J].J Cell Commun Signal,2018,12(1):171-179.
20 Teh J,Narasimhan V,Schultz S,et al.Re:pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].Eur Urol,2019,76:126-127.
21 Llovet J,Shepard KV,Finn RS,et al.A phase Ib trial of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(uHCC):Updated results[J].Ann Oncol,2019,30(Suppl 5):286-287.
22 Wang J,Zhang Z,Zhang F,et al.Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma:a phase II study[J].Ann Oncol,2019,30(Supplement 9):171.
23 Chen M,Yang S,Fan L,et al.Combined antiangiogenic therapy and immunotherapy is effective for pancreatic cancer with mismatch repair proficiency but high tumor mutation burden:a case report[J].Pancreas,2019,48(9):1232-1236.
24 Sharma NS,Gupta VK,Garrido VT,et al.Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy[J].J Clin Invest,2020,130(1):451-465.
25 Rhim AD,Oberstein PE,Thomas DH,et al.Stromal elements act to restrain,rather than support,pancreatic ductal adenocarcinoma[J].Cancer Cell,2014,25(6):735-747.
26 Jiang H,Hegde S,Knolhoff BL,et al.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy[J].Nat Med,2016,22:851-860.
27 Panni RZ,Herndon JM,Zuo C,et al.Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies[J].Sci Transl Med,2019,11(499):9240.
28 Mace TA,Shakya R,Pitarresi JR,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
29 Rotte A,Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J].J Exp Clin Cancer Res,2019,38(1):255.
30 Mitchell TC,Hamid O,Smith DC,et al.Preliminary results from a Phase I/II study of epacadostat(incb024360)in combination with pembrolizumab in patients with selected advanced cancers[J].J Clin Oncol,2018,36(32):3223-3230.
31 Duraiswamy J,Kaluza KM,Freeman GJ,et al.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors[J].Cancer Res,2013,73(12):3591-3603.
32 O'Reilly EM,Oh DY,Dhani N,et al.Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma:a phase 2 randomized clinical Trial[J].JAMA Oncol,2019,5(10):1431-1438.

[1]	ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei. Research status of neoadjuvant therapy for pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 64-68.
[2]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[3]	WANG Liangliang, DING Gaoheng, CHEN Lili, WU Jianjun, LIU Yuqin, WEI Xingmin. Trends of incidence and mortality of pancreatic cancer in Gansu cancer registration areas,2009—2015 [J]. Journal of Practical Oncology, 2021, 35(3): 200-206.
[4]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[5]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[6]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[7]	YANG Lei, SU Dan, LOU Changjie. Diagnosis and treatment of patients with hepatobiliary and pancreatic malignant tumor during and after the epidemic of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 107-110.
[8]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[9]	LUO Gan, YI Chao, YIMAMUMAIMAITIJIANGo Abula, XU Lin, YIN Jiwei, DING Wei. Expression of Notch signaling pathway in pancreatic cancer and its role [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 1-7.
[10]	ZHAO Xiangxuan,WEN Feng,LU Zaiming. The role of apoptosis in pancreatic cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 375-379.
[11]	PEI Lei, CAI Ceng, MAO Rui, Ailijang.Tu-er-xun, ZHAO Huarong, ZHANG Hua, BAO Yongxing. Prognostic analysis of 313 aged pancreatic cancer patients in hospital treatment between Uygur and Han nationality in Xinjiang area [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 1-6.
[12]	LIU Xian, REN Gang, LI Liqin, ZHU Fuhai, XIA Tingyi. Analysis of relative factors on gastrointestinal toxicity with TOMO hypofractioned radiotherapy for pancreatic adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 481-486.
[13]	WANG Fa,WANG Honghui. Advance of transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 447-451.
[14]	XU Jingjing,YANG Ming,ZHAO Juan,ZHOU Yanhua,ZHANG Yanqiao. Clinical analysis of prognostic factors in the postoperative pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 543-547.
[15]	ZHAN Chao,XU Haitao,ZHAO Liang,SUN Jianmin,DONG Wei,SUN Chengming,JIN Yu,ZHANG Yubao. The clinical research of enteral and parenteral nutritional support in postoperative patients of pancreaticoduodenectomy [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(3): 225-227.

Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments